

C.E. Wainwright has received income on a per patient basis: in 2008 from Novartis Pharmaceuticals Corporation for a randomised, open-label, multicentre, phase III trial to assess the safety of tobramycin inhalation powder compared to TOBI® in CF subjects; in 2008–2009 from Gilead Sciences, Inc. for a phase 3, open-label follow-on study of multiple courses of aztreonam lysine for inhalation (AI) in cystic fibrosis patients (AIR-CF3) (006 Study), Protocol CP-AI-007 (a phase 3, double-blind, multicentre, multi-national, randomised, placebo-controlled trial evaluating aztreonam lysinate for inhalation in cystic fibrosis patients with pulmonary *P. aeruginosa* (AIR-CF1)) and GS-US-205-0117 (a double blind, multi-centre, multinational, randomized, placebo-controlled trial evaluating aztreonam lysine for inhalation in patients with cystic fibrosis, mild lung disease, and *P. aeruginosa* (AIR-CF4)); in 2010–2012 from Vertex Pharmaceuticals Inc. for a phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of VX 770 in subjects with cystic fibrosis and the G551D mutation, a phase 3, 2-part, randomized, double-blind, placebo-controlled, parallel group study to evaluate the pharmacokinetics, efficacy and safety of VX 770 in subjects aged 6 – 11 years with cystic fibrosis and the G551D mutation and VX08-770-105 (an open-label, rollover study to evaluate the long term safety and efficacy of VX 770 in subjects with cystic fibrosis. The author has received other reimbursement from Novartis Pharmaceuticals Corporation in the form of: TOBI® supplied by Pathogenesis, Chiron, and Novartis for the ACFBAL study between 1999 and 2009; acting on international Drug Advisory Board for Novartis regarding TOBI/TIP European CF meeting Valencia 2010; presenting for the Novartis sponsored CF Symposium at European CF meeting Valencia 2010 (1 night's accommodation provided); and an economy flight return Brisbane to Melbourne to present to PBAC 9th March 2011. She has received reimbursement from L.E.K. Consulting for a Consultation Interview regarding CF Studies, from Vertex Pharmaceuticals Inc. for acting as a Consultant on the Vertex Physician Pediatric CF Advisory Board, from Lind Publishing for the CFNN Review of European CF Meeting Valencia 2010, and from Gilead Sciences, Inc. in the form of an AZLI Advisory Board Honorarium.